<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Alternative Extended-Release Minoxidil Formulations</title>
  <style>
    /* Default styles provided by pandoc.
    ** See https://pandoc.org/MANUAL.html#variables-for-html for config info.
    */
    html {
      color: #1a1a1a;
      background-color: #fdfdfd;
    }
    body {
      margin: 0 auto;
      max-width: 36em;
      padding-left: 50px;
      padding-right: 50px;
      padding-top: 50px;
      padding-bottom: 50px;
      hyphens: auto;
      overflow-wrap: break-word;
      text-rendering: optimizeLegibility;
      font-kerning: normal;
    }
    @media (max-width: 600px) {
      body {
        font-size: 0.9em;
        padding: 12px;
      }
      h1 {
        font-size: 1.8em;
      }
    }
    @media print {
      html {
        background-color: white;
      }
      body {
        background-color: transparent;
        color: black;
        font-size: 12pt;
      }
      p, h2, h3 {
        orphans: 3;
        widows: 3;
      }
      h2, h3, h4 {
        page-break-after: avoid;
      }
    }
    p {
      margin: 1em 0;
    }
    a {
      color: #1a1a1a;
    }
    a:visited {
      color: #1a1a1a;
    }
    img {
      max-width: 100%;
    }
    svg {
      height: auto;
      max-width: 100%;
    }
    h1, h2, h3, h4, h5, h6 {
      margin-top: 1.4em;
    }
    h5, h6 {
      font-size: 1em;
      font-style: italic;
    }
    h6 {
      font-weight: normal;
    }
    ol, ul {
      padding-left: 1.7em;
      margin-top: 1em;
    }
    li > ol, li > ul {
      margin-top: 0;
    }
    blockquote {
      margin: 1em 0 1em 1.7em;
      padding-left: 1em;
      border-left: 2px solid #e6e6e6;
      color: #606060;
    }
    code {
      font-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;
      font-size: 85%;
      margin: 0;
      hyphens: manual;
    }
    pre {
      margin: 1em 0;
      overflow: auto;
    }
    pre code {
      padding: 0;
      overflow: visible;
      overflow-wrap: normal;
    }
    .sourceCode {
     background-color: transparent;
     overflow: visible;
    }
    hr {
      border: none;
      border-top: 1px solid #1a1a1a;
      height: 1px;
      margin: 1em 0;
    }
    table {
      margin: 1em 0;
      border-collapse: collapse;
      width: 100%;
      overflow-x: auto;
      display: block;
      font-variant-numeric: lining-nums tabular-nums;
    }
    table caption {
      margin-bottom: 0.75em;
    }
    tbody {
      margin-top: 0.5em;
      border-top: 1px solid #1a1a1a;
      border-bottom: 1px solid #1a1a1a;
    }
    th {
      border-top: 1px solid #1a1a1a;
      padding: 0.25em 0.5em 0.25em 0.5em;
    }
    td {
      padding: 0.125em 0.5em 0.25em 0.5em;
    }
    header {
      margin-bottom: 4em;
      text-align: center;
    }
    #TOC li {
      list-style: none;
    }
    #TOC ul {
      padding-left: 1.3em;
    }
    #TOC > ul {
      padding-left: 0;
    }
    #TOC a:not(:hover) {
      text-decoration: none;
    }
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
  </style>
</head>
<body>
<header id="title-block-header">
<h1 class="title">Alternative Extended-Release Minoxidil
Formulations</h1>
</header>
<h1 id="alternative-extended-release-minoxidil-formulations">Alternative
Extended-Release Minoxidil Formulations</h1>
<h2
id="patent-design-around-strategy-for-veradermics-hpmc-matrix-claims">Patent
Design-Around Strategy for Veradermics’ HPMC Matrix Claims</h2>
<p><strong>Prepared:</strong> February 2026 <strong>Updated:</strong>
February 5, 2026 (8.5mg dose formulations) <strong>Purpose:</strong>
Competitive product development - formulations designed to avoid
Veradermics patent WO2024091572A1 / US12268688B2</p>
<hr />
<h2 id="executive-summary">Executive Summary</h2>
<p>Veradermics’ patent claims specifically cover HPMC-based
(hydroxypropyl methylcellulose) matrix tablets for extended-release oral
minoxidil. This document presents <strong>five alternative formulation
approaches</strong> using fundamentally different release mechanisms
that are likely outside their patent claims:</p>
<ol type="1">
<li><strong>Elementary Osmotic Pump (EOP)</strong> - Osmotic
pressure-driven release</li>
<li><strong>Controlled Porosity Osmotic Pump (CPOP)</strong> - Porous
membrane osmotic system</li>
<li><strong>Multi-Particulate Pellet System (MUPS)</strong> -
Ethylcellulose-coated pellets in capsule</li>
<li><strong>Lipid Matrix Tablet</strong> - Glyceryl
behenate/palmitostearate matrix</li>
<li><strong>Bi-Layer Push-Pull Osmotic Tablet</strong> - Two-compartment
mechanical pump</li>
</ol>
<hr />
<h2 id="target-product-profile">Target Product Profile</h2>
<table>
<colgroup>
<col style="width: 36%" />
<col style="width: 26%" />
<col style="width: 36%" />
</colgroup>
<thead>
<tr>
<th>Parameter</th>
<th>Target</th>
<th>Rationale</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose per unit</strong></td>
<td><strong>8.5 mg</strong></td>
<td>Matches Veradermics VDPHL01 clinical dose</td>
</tr>
<tr>
<td><strong>Total daily dose</strong></td>
<td><strong>17 mg (8.5 mg × 2)</strong></td>
<td>Matches Veradermics BID regimen</td>
</tr>
<tr>
<td>Release duration</td>
<td>10-12 hours</td>
<td>Covers 12-hour dosing interval</td>
</tr>
<tr>
<td><strong>Target Cmax</strong></td>
<td><strong>6-10 ng/mL</strong></td>
<td>Matches Veradermics (~7-8 ng/mL); well below cardiac threshold (20
ng/mL)</td>
</tr>
<tr>
<td><strong>Target Tmax</strong></td>
<td><strong>2-4 hours</strong></td>
<td>Delayed vs immediate release</td>
</tr>
<tr>
<td><strong>Dosing frequency</strong></td>
<td><strong>Twice daily (q12h)</strong></td>
<td>Matches Veradermics regimen</td>
</tr>
<tr>
<td>Hair growth threshold</td>
<td>&gt;1.62 ng/mL</td>
<td>Minimum effective concentration for 10-12 hours</td>
</tr>
<tr>
<td>Cardiac activity threshold</td>
<td>&lt;20 ng/mL</td>
<td>Must stay below to avoid CV side effects</td>
</tr>
</tbody>
</table>
<h3 id="key-pk-thresholds-from-veradermics-clinical-data">Key PK
Thresholds (from Veradermics clinical data)</h3>
<table>
<colgroup>
<col style="width: 34%" />
<col style="width: 21%" />
<col style="width: 43%" />
</colgroup>
<thead>
<tr>
<th>Threshold</th>
<th>Value</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cardiac activity threshold</strong></td>
<td>20 ng/mL</td>
<td>Above this: tachycardia, hypotension risk</td>
</tr>
<tr>
<td><strong>Ideal therapeutic range</strong></td>
<td>5-15 ng/mL</td>
<td>Efficacy without cardiac effects</td>
</tr>
<tr>
<td><strong>Hair growth threshold</strong></td>
<td>1.62 ng/mL</td>
<td>Minimum for hair follicle stimulation</td>
</tr>
<tr>
<td><strong>Veradermics VDPHL01 Cmax</strong></td>
<td>~7-8 ng/mL</td>
<td>Their actual achieved Cmax</td>
</tr>
<tr>
<td><strong>IR minoxidil 5mg Cmax</strong></td>
<td>~22 ng/mL</td>
<td>Exceeds cardiac threshold</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="minoxidil-physicochemical-properties">Minoxidil Physicochemical
Properties</h2>
<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
<th>Implication</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCS Classification</td>
<td>Class II</td>
<td>Low solubility, high permeability</td>
</tr>
<tr>
<td>Aqueous solubility</td>
<td>~2.2 mg/mL</td>
<td>May need solubility enhancement</td>
</tr>
<tr>
<td>Molecular weight</td>
<td>209.25 g/mol</td>
<td>Small molecule, good diffusion</td>
</tr>
<tr>
<td>pKa</td>
<td>4.6</td>
<td>Weak base</td>
</tr>
<tr>
<td>LogP</td>
<td>1.24</td>
<td>Moderate lipophilicity</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="formulation-1-elementary-osmotic-pump-tablet-eop">FORMULATION 1:
Elementary Osmotic Pump Tablet (EOP)</h2>
<h3 id="mechanism">Mechanism</h3>
<p>Osmotic pressure drives drug solution through laser-drilled orifice.
Fundamentally different from HPMC matrix swelling/erosion - uses
cellulose acetate semipermeable membrane with zero-order release
kinetics.</p>
<h3 id="core-tablet-composition-per-tablet">Core Tablet Composition (per
tablet)</h3>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 31%" />
<col style="width: 17%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>Amount (mg)</th>
<th>% w/w</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minoxidil</strong></td>
<td><strong>8.5</strong></td>
<td><strong>3.4%</strong></td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>100.0</td>
<td>40.0%</td>
<td>Osmotic agent (osmogent)</td>
</tr>
<tr>
<td>Mannitol</td>
<td>62.5</td>
<td>25.0%</td>
<td>Osmotic agent + filler</td>
</tr>
<tr>
<td>Polyethylene oxide (MW 200K)</td>
<td>50.0</td>
<td>20.0%</td>
<td>Suspending/swelling agent</td>
</tr>
<tr>
<td>Povidone K30</td>
<td>18.75</td>
<td>7.5%</td>
<td>Binder</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>5.0</td>
<td>2.0%</td>
<td>Lubricant</td>
</tr>
<tr>
<td>Colloidal silicon dioxide</td>
<td>5.25</td>
<td>2.1%</td>
<td>Glidant</td>
</tr>
<tr>
<td><strong>Total core weight</strong></td>
<td><strong>250.0</strong></td>
<td><strong>100%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="semipermeable-membrane-coating">Semipermeable Membrane
Coating</h3>
<table>
<colgroup>
<col style="width: 37%" />
<col style="width: 27%" />
<col style="width: 34%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>Amount</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose acetate (398-10)</td>
<td>85% of coating</td>
<td>Semipermeable membrane former</td>
</tr>
<tr>
<td>PEG 3350</td>
<td>15% of coating</td>
<td>Plasticizer/pore former</td>
</tr>
<tr>
<td>Coating weight gain</td>
<td>8-10%</td>
<td>Controls water permeation rate</td>
</tr>
<tr>
<td>Orifice diameter</td>
<td>0.5 mm</td>
<td>Laser-drilled delivery port</td>
</tr>
</tbody>
</table>
<h3 id="manufacturing-process">Manufacturing Process</h3>
<ol type="1">
<li>Wet granulate minoxidil + osmogents + binder using purified
water</li>
<li>Dry at 50°C to &lt;2% moisture content</li>
<li>Mill through 30-mesh screen</li>
<li>Blend with lubricant/glidant for 5 minutes</li>
<li>Direct compress into 9mm round biconvex tablets at 12 kN</li>
<li>Spray coat with cellulose acetate/PEG solution (acetone:water 9:1)
in perforated pan coater</li>
<li>Laser drill single 0.5mm orifice on one face</li>
</ol>
<h3 id="expected-release-profile">Expected Release Profile</h3>
<ul>
<li>Lag time: 1-2 hours (membrane hydration)</li>
<li>Zero-order release: 2-12 hours</li>
<li><blockquote>
<p>85% release by 14 hours</p>
</blockquote></li>
</ul>
<h3 id="key-patent-differentiation">Key Patent Differentiation</h3>
<ul>
<li>No HPMC in formulation</li>
<li>Osmotic mechanism vs. gel diffusion/erosion</li>
<li>Cellulose acetate membrane vs. HPMC matrix</li>
<li>Requires laser-drilled orifice</li>
</ul>
<hr />
<h2 id="formulation-2-controlled-porosity-osmotic-pump-cpop">FORMULATION
2: Controlled Porosity Osmotic Pump (CPOP)</h2>
<h3 id="mechanism-1">Mechanism</h3>
<p>Water-soluble pore formers (sorbitol) create microchannels in
cellulose acetate membrane upon contact with GI fluids. No laser
drilling required. Distinct from matrix systems.</p>
<h3 id="core-tablet-composition-per-tablet-1">Core Tablet Composition
(per tablet)</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Amount (mg)</th>
<th>% w/w</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minoxidil</strong></td>
<td><strong>8.5</strong></td>
<td><strong>4.25%</strong></td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Fructose</td>
<td>80.0</td>
<td>40.0%</td>
<td>Osmotic agent</td>
</tr>
<tr>
<td>Lactose monohydrate</td>
<td>55.0</td>
<td>27.5%</td>
<td>Filler + osmotic agent</td>
</tr>
<tr>
<td>PEG 6000</td>
<td>30.0</td>
<td>15.0%</td>
<td>Solubilizer + osmogent</td>
</tr>
<tr>
<td>Croscarmellose sodium</td>
<td>13.0</td>
<td>6.5%</td>
<td>Wicking agent</td>
</tr>
<tr>
<td>Povidone K29/32</td>
<td>7.5</td>
<td>3.75%</td>
<td>Binder</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>6.0</td>
<td>3.0%</td>
<td>Lubricant</td>
</tr>
<tr>
<td><strong>Total core weight</strong></td>
<td><strong>200.0</strong></td>
<td><strong>100%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="controlled-porosity-membrane">Controlled Porosity Membrane</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>% of coating</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose acetate (CA 320S)</td>
<td>70%</td>
<td>Membrane former</td>
</tr>
<tr>
<td>Sorbitol</td>
<td>20%</td>
<td>Water-soluble pore former</td>
</tr>
<tr>
<td>PEG 400</td>
<td>10%</td>
<td>Plasticizer</td>
</tr>
<tr>
<td><strong>Coating weight gain</strong></td>
<td><strong>6-8%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="manufacturing-process-1">Manufacturing Process</h3>
<ol type="1">
<li>Blend all core components</li>
<li>Wet granulate with PVP solution</li>
<li>Dry and compress into 8mm tablets</li>
<li>Prepare coating solution in acetone:methanol (8:2)</li>
<li>Spray coat in fluidized bed coater</li>
<li>No drilling required - pores form in situ</li>
</ol>
<h3 id="expected-release-profile-1">Expected Release Profile</h3>
<ul>
<li>Initial lag: 30-60 minutes</li>
<li>Controlled release: 1-12 hours</li>
<li><blockquote>
<p>90% release by 14 hours</p>
</blockquote></li>
</ul>
<h3 id="key-patent-differentiation-1">Key Patent Differentiation</h3>
<ul>
<li>Porous membrane system vs. gel matrix</li>
<li>No HPMC used</li>
<li>In-situ pore formation vs. pre-formed matrix</li>
<li>Osmotic driving force vs. concentration gradient</li>
</ul>
<hr />
<h2
id="formulation-3-multi-particulate-pellet-system-mups-capsule">FORMULATION
3: Multi-Particulate Pellet System (MUPS Capsule)</h2>
<h3 id="mechanism-2">Mechanism</h3>
<p>Drug-loaded pellets with rate-controlling ethylcellulose/Eudragit
polymer coating. Completely different architecture from monolithic
matrix tablet. Drug release by diffusion through coating membrane.</p>
<h3 id="pellet-core-drug-layered-on-sugar-spheres">Pellet Core
(drug-layered on sugar spheres)</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Amount per capsule</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sugar spheres (25-30 mesh, 710-850 μm)</td>
<td>255 mg</td>
<td>Inert core</td>
</tr>
<tr>
<td><strong>Minoxidil</strong></td>
<td><strong>8.5 mg</strong></td>
<td>Active ingredient</td>
</tr>
<tr>
<td>HPMC E5 (binder solution)</td>
<td>17 mg</td>
<td>Drug layering binder</td>
</tr>
<tr>
<td>Talc</td>
<td>8.5 mg</td>
<td>Anti-tacking agent</td>
</tr>
</tbody>
</table>
<h3 id="seal-coat-between-drug-layer-and-sr-coating">Seal Coat (between
drug layer and SR coating)</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPMC E5</td>
<td>Barrier layer</td>
</tr>
<tr>
<td>Weight gain</td>
<td>2-3%</td>
</tr>
</tbody>
</table>
<h3 id="sustained-release-coating">Sustained-Release Coating</h3>
<table>
<colgroup>
<col style="width: 31%" />
<col style="width: 40%" />
<col style="width: 28%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>% of coating</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ethylcellulose (Surelease® E-7-19040)</td>
<td>60%</td>
<td>Rate-controlling polymer</td>
</tr>
<tr>
<td>Eudragit® RS 30D</td>
<td>30%</td>
<td>Sustained release modifier (low permeability)</td>
</tr>
<tr>
<td>Triethyl citrate</td>
<td>10%</td>
<td>Plasticizer</td>
</tr>
<tr>
<td><strong>Coating weight gain</strong></td>
<td><strong>18-22%</strong></td>
<td>Controls release rate</td>
</tr>
</tbody>
</table>
<h3 id="capsule-fill">Capsule Fill</h3>
<ul>
<li>Fill ~290 mg coated pellets into <strong>Size 1</strong> hard
gelatin or HPMC capsule</li>
<li>Option: Blend pellets with different coating levels (15%, 18%, 22%)
for customized release profile</li>
</ul>
<h3 id="manufacturing-process-2">Manufacturing Process</h3>
<ol type="1">
<li>Load sugar spheres into fluidized bed coater (Wurster insert)</li>
<li>Apply drug layer solution (minoxidil + HPMC E5 in water:ethanol
7:3)</li>
<li>Apply seal coat (HPMC E5 in water)</li>
<li>Apply sustained-release coating (aqueous dispersion)</li>
<li>Cure at 40°C/75% RH for 24 hours</li>
<li>Fill into capsules</li>
</ol>
<h3 id="expected-release-profile-2">Expected Release Profile</h3>
<ul>
<li>20-30% release at 2 hours</li>
<li>50-60% release at 6 hours</li>
<li><blockquote>
<p>85% release at 12 hours</p>
</blockquote></li>
</ul>
<h3 id="key-patent-differentiation-2">Key Patent Differentiation</h3>
<ul>
<li><strong>Multi-particulate</strong> vs. monolithic tablet</li>
<li><strong>Ethylcellulose-based</strong> coating vs. HPMC matrix</li>
<li><strong>Capsule</strong> dosage form vs. tablet</li>
<li><strong>Diffusion through coating</strong> vs. gel erosion</li>
<li>Reduced dose-dumping risk</li>
<li>More predictable GI transit</li>
</ul>
<h3 id="advantages">Advantages</h3>
<ul>
<li>Flexible release profile (adjust coating level)</li>
<li>Lower inter-subject variability</li>
<li>Can combine with immediate-release pellets</li>
<li>Well-established regulatory pathway</li>
<li><strong>Lowest dose-dumping risk at 8.5mg dose</strong></li>
</ul>
<hr />
<h2 id="formulation-4-lipid-matrix-tablet-recommended">FORMULATION 4:
Lipid Matrix Tablet (RECOMMENDED)</h2>
<h3 id="mechanism-3">Mechanism</h3>
<p>Drug dispersed in waxy lipid matrix (glyceryl
behenate/palmitostearate). Release by erosion and diffusion through
hydrophobic lipid. Fundamentally different from hydrophilic HPMC gel
matrix.</p>
<h3
id="tablet-composition-per-tablet---optimized-for-veradermics-matching-pk">Tablet
Composition (per tablet) - OPTIMIZED FOR VERADERMICS-MATCHING PK</h3>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 31%" />
<col style="width: 17%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>Amount (mg)</th>
<th>% w/w</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minoxidil</strong></td>
<td><strong>8.5</strong></td>
<td><strong>3.4%</strong></td>
<td>Active ingredient</td>
</tr>
<tr>
<td>Compritol® 888 ATO (glyceryl behenate)</td>
<td><strong>112.5</strong></td>
<td><strong>45.0%</strong></td>
<td>Lipid matrix former (increased for lower Cmax)</td>
</tr>
<tr>
<td>Precirol® ATO 5 (glyceryl palmitostearate)</td>
<td><strong>30.0</strong></td>
<td><strong>12.0%</strong></td>
<td>Secondary lipid</td>
</tr>
<tr>
<td>PEG 6000</td>
<td><strong>12.5</strong></td>
<td><strong>5.0%</strong></td>
<td>Pore former (reduced for slower release)</td>
</tr>
<tr>
<td>Microcrystalline cellulose (Avicel PH-102)</td>
<td>55.0</td>
<td>22.0%</td>
<td>Filler/compressibility aid</td>
</tr>
<tr>
<td>Lactose monohydrate</td>
<td>17.5</td>
<td>7.0%</td>
<td>Filler</td>
</tr>
<tr>
<td>Poloxamer 188</td>
<td><strong>3.75</strong></td>
<td><strong>1.5%</strong></td>
<td>Surfactant (wetting)</td>
</tr>
<tr>
<td>Colloidal silicon dioxide (Aerosil 200)</td>
<td>5.0</td>
<td>2.0%</td>
<td>Glidant</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>5.25</td>
<td>2.1%</td>
<td>Lubricant</td>
</tr>
<tr>
<td><strong>Total tablet weight</strong></td>
<td><strong>250.0</strong></td>
<td><strong>100%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>Total lipid content: 57%</strong> (optimized for Cmax ~6-10
ng/mL to match Veradermics)</p>
<h3 id="manufacturing-process-melt-granulation">Manufacturing Process
(Melt Granulation)</h3>
<ol type="1">
<li>Preheat mixer to 75-80°C</li>
<li>Add Compritol + Precirol, allow to melt completely</li>
<li>Add minoxidil, mix until dissolved/dispersed (5 min)</li>
<li>Add MCC and lactose, mix thoroughly (10 min)</li>
<li>Cool to room temperature while mixing</li>
<li>Mill solidified mass through 20-mesh screen</li>
<li>Blend with colloidal silica and magnesium stearate (3 min)</li>
<li>Direct compress into 9mm tablets at 12 kN</li>
</ol>
<h3 id="alternative-hot-melt-extrusion">Alternative: Hot Melt
Extrusion</h3>
<ol type="1">
<li>Premix minoxidil with lipids</li>
<li>Extrude at 70-75°C through twin-screw extruder</li>
<li>Mill extrudate to granules</li>
<li>Blend and compress</li>
</ol>
<h3 id="expected-release-profile-target-for-cmax-6-10-ngml">Expected
Release Profile (Target for Cmax ~6-10 ng/mL)</h3>
<ul>
<li>Near zero-order release kinetics</li>
<li><strong>15-20% release at 1 hour</strong> (reduced initial
burst)</li>
<li><strong>40-50% release at 4 hours</strong></li>
<li><strong>65-75% release at 8 hours</strong></li>
<li><strong>&gt;80% release at 12 hours</strong></li>
<li>Maintain plasma levels &gt;1.62 ng/mL (hair growth threshold) for
10-12 hours</li>
</ul>
<h3 id="key-patent-differentiation-3">Key Patent Differentiation</h3>
<ul>
<li><strong>Lipid-based</strong> vs. hydrophilic polymer matrix</li>
<li><strong>Hydrophobic matrix</strong> vs. hydrophilic gel</li>
<li>Drug release via <strong>lipid erosion + diffusion</strong></li>
<li><strong>pH-independent</strong> release (lipids insoluble at all
pH)</li>
<li>No polymers used in matrix (only lipid excipients)</li>
</ul>
<h3 id="advantages-1">Advantages</h3>
<ul>
<li>Simple manufacturing (melt granulation)</li>
<li>pH-independent release</li>
<li>Good stability</li>
<li>Low cost excipients</li>
</ul>
<h3 id="caution">Caution</h3>
<ul>
<li>Potential food effect with high-fat meals (monitor in PK
studies)</li>
</ul>
<hr />
<h2 id="formulation-5-bi-layer-push-pull-osmotic-tablet">FORMULATION 5:
Bi-Layer Push-Pull Osmotic Tablet</h2>
<h3 id="mechanism-4">Mechanism</h3>
<p>Two-compartment system with osmotic “push” layer that expands and
drives drug from “pull” layer through laser-drilled orifice. Mechanical
pumping action.</p>
<h3 id="drug-layer-pull-layer---120-mg">Drug Layer (Pull Layer) - 120
mg</h3>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 31%" />
<col style="width: 17%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>Amount (mg)</th>
<th>% w/w</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Minoxidil</strong></td>
<td><strong>8.5</strong></td>
<td><strong>7.1%</strong></td>
<td>Active ingredient</td>
</tr>
<tr>
<td>PEG 400</td>
<td>12.0</td>
<td>10.0%</td>
<td>Solubility enhancer</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>36.0</td>
<td>30.0%</td>
<td>Osmogent</td>
</tr>
<tr>
<td>Polyethylene oxide (MW 100K)</td>
<td>52.5</td>
<td>43.75%</td>
<td>Drug carrier/suspending agent</td>
</tr>
<tr>
<td>Povidone K30</td>
<td>11.0</td>
<td>9.15%</td>
<td>Binder</td>
</tr>
<tr>
<td><strong>Total drug layer</strong></td>
<td><strong>120.0</strong></td>
<td><strong>100%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="push-layer---100-mg">Push Layer - 100 mg</h3>
<table>
<colgroup>
<col style="width: 26%" />
<col style="width: 31%" />
<col style="width: 17%" />
<col style="width: 24%" />
</colgroup>
<thead>
<tr>
<th>Component</th>
<th>Amount (mg)</th>
<th>% w/w</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene oxide (MW 7M)</td>
<td>60.0</td>
<td>60.0%</td>
<td>High MW expanding polymer</td>
</tr>
<tr>
<td>Sodium chloride</td>
<td>25.0</td>
<td>25.0%</td>
<td>Osmogent</td>
</tr>
<tr>
<td>Ferric oxide (red)</td>
<td>5.0</td>
<td>5.0%</td>
<td>Colorant/layer identifier</td>
</tr>
<tr>
<td>Hydroxypropyl cellulose (Klucel EF)</td>
<td>10.0</td>
<td>10.0%</td>
<td>Binder</td>
</tr>
<tr>
<td><strong>Total push layer</strong></td>
<td><strong>100.0</strong></td>
<td><strong>100%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="membrane-coating">Membrane Coating</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>% of coating</th>
<th>Function</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cellulose acetate</td>
<td>80%</td>
<td>Semipermeable membrane</td>
</tr>
<tr>
<td>PEG 3350</td>
<td>20%</td>
<td>Plasticizer</td>
</tr>
<tr>
<td><strong>Weight gain</strong></td>
<td><strong>8%</strong></td>
<td></td>
</tr>
</tbody>
</table>
<h3 id="assembly">Assembly</h3>
<ul>
<li>Compress drug layer first</li>
<li>Add push layer on top, compress bi-layer tablet</li>
<li><strong>Total tablet: 220 mg</strong>, 9mm caplet shape</li>
<li>Coat with cellulose acetate membrane</li>
<li>Laser drill single 0.4 mm orifice on drug layer side</li>
</ul>
<h3 id="manufacturing-process-3">Manufacturing Process</h3>
<ol type="1">
<li>Prepare drug layer granulation (wet granulate, dry, mill)</li>
<li>Prepare push layer granulation separately</li>
<li>Fill drug layer into die, pre-compress lightly</li>
<li>Add push layer, final compression</li>
<li>Spray coat bi-layer tablets</li>
<li>Laser drill orifice (positioned on drug layer face)</li>
</ol>
<h3 id="expected-release-profile-3">Expected Release Profile</h3>
<ul>
<li>Lag time: 1-2 hours</li>
<li>Zero-order release: 2-14 hours</li>
<li><blockquote>
<p>90% release by 16 hours</p>
</blockquote></li>
</ul>
<h3 id="key-patent-differentiation-4">Key Patent Differentiation</h3>
<ul>
<li><strong>Bi-compartment</strong> vs. single-layer matrix</li>
<li><strong>Mechanical pumping action</strong> vs. passive
diffusion</li>
<li>Uses <strong>polyethylene oxide</strong>, not HPMC</li>
<li><strong>Osmotic pressure</strong> drives release, not concentration
gradient</li>
</ul>
<hr />
<h2 id="comparative-analysis">Comparative Analysis</h2>
<table>
<colgroup>
<col style="width: 11%" />
<col style="width: 33%" />
<col style="width: 6%" />
<col style="width: 7%" />
<col style="width: 7%" />
<col style="width: 18%" />
<col style="width: 14%" />
</colgroup>
<thead>
<tr>
<th>Feature</th>
<th>Veradermics (HPMC Matrix)</th>
<th>EOP</th>
<th>CPOP</th>
<th>MUPS</th>
<th>Lipid Matrix</th>
<th>Push-Pull</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose</strong></td>
<td>8.5 mg</td>
<td>8.5 mg</td>
<td>8.5 mg</td>
<td>8.5 mg</td>
<td>8.5 mg</td>
<td>8.5 mg</td>
</tr>
<tr>
<td><strong>Primary polymer/excipient</strong></td>
<td>HPMC K4M/K200M</td>
<td>Cellulose acetate</td>
<td>Cellulose acetate</td>
<td>Ethylcellulose</td>
<td>Compritol/Precirol</td>
<td>PEO/Cellulose acetate</td>
</tr>
<tr>
<td><strong>Release mechanism</strong></td>
<td>Gel diffusion/erosion</td>
<td>Osmotic pump</td>
<td>Osmotic (porous membrane)</td>
<td>Coating diffusion</td>
<td>Lipid erosion</td>
<td>Osmotic push-pull</td>
</tr>
<tr>
<td><strong>Dosage form</strong></td>
<td>Monolithic tablet</td>
<td>Coated tablet</td>
<td>Coated tablet</td>
<td>Capsule with pellets</td>
<td>Monolithic tablet</td>
<td>Bi-layer tablet</td>
</tr>
<tr>
<td><strong>Tablet/capsule weight</strong></td>
<td>~150-200 mg</td>
<td>250 mg</td>
<td>200 mg</td>
<td>~290 mg (Size 1 cap)</td>
<td>250 mg</td>
<td>220 mg</td>
</tr>
<tr>
<td><strong>Orifice required</strong></td>
<td>No</td>
<td>Yes (laser)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>Yes (laser)</td>
</tr>
<tr>
<td><strong>pH dependency</strong></td>
<td>Some</td>
<td>Minimal</td>
<td>Minimal</td>
<td>Minimal</td>
<td>None</td>
<td>Minimal</td>
</tr>
<tr>
<td><strong>Food effect risk</strong></td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Low</td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Dose-dumping risk</strong></td>
<td>Moderate</td>
<td>Low</td>
<td>Low</td>
<td><strong>Lowest</strong></td>
<td>Moderate</td>
<td>Low</td>
</tr>
<tr>
<td><strong>Manufacturing complexity</strong></td>
<td>Low</td>
<td>High</td>
<td>Medium</td>
<td>Medium</td>
<td>Low-Medium</td>
<td>High</td>
</tr>
<tr>
<td><strong>Equipment needs</strong></td>
<td>Standard</td>
<td>Laser drill</td>
<td>Standard coating</td>
<td>Wurster coater</td>
<td>Melt granulator</td>
<td>Laser drill</td>
</tr>
<tr>
<td><strong>Regulatory precedent</strong></td>
<td>Common</td>
<td>OROS products</td>
<td>Less common</td>
<td>Common (generic ER)</td>
<td>Moderate</td>
<td>OROS products</td>
</tr>
</tbody>
</table>
<hr />
<h2 id="recommended-development-priority">Recommended Development
Priority</h2>
<h3 id="first-choice-formulation-3-multi-particulatemups">First Choice:
FORMULATION 3 (Multi-Particulate/MUPS)</h3>
<p><strong>Rationale:</strong> 1. <strong>Lowest dose-dumping
risk</strong> - critical at 8.5mg where dose-dump could cause cardiac
effects 2. Most established regulatory pathway for ER generics 3. No
specialized equipment (laser drilling) required 4. Ethylcellulose
coatings are well-characterized and approved 5. Flexible release profile
customization by adjusting coating level 6. Lower manufacturing
complexity than osmotic systems 7. Clear differentiation from HPMC
matrix claims</p>
<h3 id="second-choice-formulation-4-lipid-matrix">Second Choice:
FORMULATION 4 (Lipid Matrix)</h3>
<p><strong>Rationale:</strong> 1. Simpler manufacturing (melt
granulation or hot melt extrusion) 2. Completely different chemistry
(lipids vs. polymers) 3. Very strong patent differentiation argument 4.
pH-independent release 5. Low-cost, readily available excipients 6. Good
stability profile 7. <strong>Caution:</strong> Monitor for food effects
in PK studies</p>
<h3 id="third-choice-formulation-2-cpop">Third Choice: FORMULATION 2
(CPOP)</h3>
<p><strong>Rationale:</strong> 1. Osmotic mechanism clearly different
from matrix 2. No laser drilling required (unlike EOP) 3. Zero-order
release kinetics 4. Food-independent absorption</p>
<hr />
<h2 id="development-considerations">Development Considerations</h2>
<h3 id="first-in-human-study-design-8.5mg-dose">First-in-Human Study
Design (8.5mg dose)</h3>
<p><strong>Recommended approach:</strong> 1. <strong>Dose
escalation:</strong> Start with 2.5mg, then 5mg, then 8.5mg 2.
<strong>Safety monitoring:</strong> Continuous ECG, BP every 30 min for
first 4 hours 3. <strong>PK sampling:</strong> Pre-dose, 0.5, 1, 2, 3,
4, 6, 8, 10, 12, 14, 16, 24 hours 4. <strong>Food effect arm:</strong>
Compare fasted vs. high-fat meal (especially for lipid matrix)</p>
<h3 id="bioequivalence-strategy">Bioequivalence Strategy</h3>
<ul>
<li>Different release mechanisms may yield different PK profiles</li>
<li>May need to target similar AUC rather than identical Cmax/Tmax</li>
<li>Consider 505(b)(2) pathway if not bioequivalent to Veradermics
product</li>
</ul>
<h3 id="stability-studies-required">Stability Studies Required</h3>
<ul>
<li>Accelerated stability (40°C/75% RH, 6 months)</li>
<li>Long-term stability (25°C/60% RH, 12-36 months)</li>
<li>Photostability (ICH Q1B)</li>
<li>Minoxidil compatibility with each matrix type</li>
</ul>
<h3 id="scale-up-considerations">Scale-Up Considerations</h3>
<ul>
<li>MUPS: Wurster coating equipment availability</li>
<li>Lipid matrix: Melt granulation or HME equipment</li>
<li>Osmotic systems: Laser drilling equipment, membrane coating
expertise</li>
</ul>
<h3 id="regulatory-pathway-options">Regulatory Pathway Options</h3>
<ol type="1">
<li><strong>505(b)(2)</strong> - Reference Veradermics’ safety/efficacy
data, own PK studies</li>
<li><strong>505(j) ANDA</strong> - If bioequivalent, but need to design
around patents</li>
<li><strong>New NDA</strong> - If claiming superiority or different
indication</li>
</ol>
<hr />
<h2
id="patent-validity-analysis-critical-issue-with-veradermics-claims">Patent
Validity Analysis: Critical Issue with Veradermics Claims</h2>
<h3
id="the-problem-claimed-pk-parameters-overlap-with-immediate-release-minoxidil">The
Problem: Claimed PK Parameters Overlap with Immediate-Release
Minoxidil</h3>
<p>Veradermics’ patent claims (US12268688B2) are written as METHOD
claims covering any “modified release pharmaceutical formulation”
achieving specific pharmacokinetic parameters:</p>
<table>
<thead>
<tr>
<th>Claim Element</th>
<th>Veradermics Patent Claims</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose range</td>
<td>3.5 - 20 mg</td>
</tr>
<tr>
<td>Cmax</td>
<td>0.25 - 20 ng/mL</td>
</tr>
<tr>
<td>Tmax</td>
<td>30 - 360 minutes (0.5 - 6 hours)</td>
</tr>
</tbody>
</table>
<h3
id="standard-immediate-release-minoxidil-pk-published-literature">Standard
Immediate-Release Minoxidil PK (Published Literature)</h3>
<p>From published pharmacokinetic studies (<a
href="https://pubmed.ncbi.nlm.nih.gov/2715373/">Fleishaker et al., J
Clin Pharmacol 1989</a>; <a
href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10806356/">PMC10806356</a>):</p>
<table>
<colgroup>
<col style="width: 14%" />
<col style="width: 24%" />
<col style="width: 34%" />
<col style="width: 26%" />
</colgroup>
<thead>
<tr>
<th>Parameter</th>
<th>IR Minoxidil 2.5mg</th>
<th>Veradermics Claimed Range</th>
<th>Falls Within Claims?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cmax</strong></td>
<td>16.8 ± 7.83 ng/mL</td>
<td>0.25 - 20 ng/mL</td>
<td><strong>YES</strong></td>
</tr>
<tr>
<td><strong>Tmax</strong></td>
<td>1 hour (60 min)</td>
<td>30 - 360 minutes</td>
<td><strong>YES</strong></td>
</tr>
</tbody>
</table>
<p><strong>Standard immediate-release minoxidil ALREADY achieves the PK
parameters claimed in the patent.</strong></p>
<h3 id="implications-for-patent-validity">Implications for Patent
Validity</h3>
<p>This creates potential invalidity arguments under 35 U.S.C.:</p>
<ol type="1">
<li><p><strong>Lack of Novelty (§102):</strong> If IR minoxidil was used
to treat hair loss before October 2022 (Veradermics’ priority date) and
achieved these PK parameters, the claims may be anticipated by prior
art.</p></li>
<li><p><strong>Obviousness (§103):</strong> It may have been obvious to
administer minoxidil at doses achieving these PK parameters for hair
loss treatment, given the extensive off-label use of oral minoxidil for
alopecia.</p></li>
<li><p><strong>Indefiniteness (§112):</strong> The claims are so broad
they would cover existing IR minoxidil use, suggesting the claims may
not particularly point out and distinctly claim the invention.</p></li>
</ol>
<h3 id="prior-art-off-label-oral-minoxidil-for-hair-loss">Prior Art:
Off-Label Oral Minoxidil for Hair Loss</h3>
<p>Oral minoxidil (Loniten®) has been used off-label for hair loss
treatment for years: - Multiple published case series and studies prior
to 2022 - Doses ranging from 0.25mg to 5mg daily - Known PK profile
achieving Cmax ~17 ng/mL at 2.5mg</p>
<h3 id="strategic-implications">Strategic Implications</h3>
<ol type="1">
<li><p><strong>For Invalidity Challenge:</strong> This analysis suggests
Veradermics’ patent claims may be vulnerable to an invalidity challenge
based on anticipation or obviousness.</p></li>
<li><p><strong>For Freedom-to-Operate:</strong> Even if our formulations
technically achieve the claimed PK parameters, we may have a strong
invalidity defense.</p></li>
<li><p><strong>For IPR/PGR:</strong> Consider filing an Inter Partes
Review (IPR) or Post-Grant Review (PGR) to challenge the patent claims
based on this prior art.</p></li>
</ol>
<h3 id="recommended-action">Recommended Action</h3>
<p>Engage patent counsel to: 1. Conduct prior art search for
publications on oral minoxidil PK for hair loss pre-dating October 2022
2. Evaluate strength of invalidity arguments 3. Consider IPR/PGR
petition to narrow or invalidate overly broad claims</p>
<hr />
<h2 id="important-caveats">Important Caveats</h2>
<ol type="1">
<li><strong>Patent freedom-to-operate analysis required</strong> - Have
IP attorney review all formulations against full Veradermics claim
set</li>
<li><strong>Formulation optimization needed</strong> - These are
starting points requiring systematic development</li>
<li><strong>In vitro-in vivo correlation (IVIVC)</strong> - Establish
relationship between dissolution and absorption</li>
<li><strong>Clinical PK studies</strong> - Required to confirm target
profile achieved</li>
<li><strong>CMC development</strong> - Full pharmaceutical development
and validation required</li>
<li><strong>IND required</strong> - Any human testing requires FDA IND
approval</li>
</ol>
<hr />
<h2 id="references">References</h2>
<ol type="1">
<li>Osmotic Pump Drug Delivery Systems - PMC (PMID: 36407821)</li>
<li>Ethylcellulose/Eudragit Coating Systems - PMC (PMID: 27478784)</li>
<li>Compritol 888 ATO Monograph - Gattefosse</li>
<li>Cellulose Acetate Membranes for Osmotic Systems - PubMed (PMID:
12056533)</li>
<li>Minoxidil Physicochemical Properties - PubChem CID 4201</li>
<li>Veradermics Patent WO2024091572A1 - Google Patents</li>
<li>Veradermics Patent US12268688B2 - USPTO</li>
</ol>
<hr />
<p><em>Document prepared for competitive intelligence and product
development purposes. Not legal advice. Consult patent attorney before
proceeding with development.</em></p>
</body>
</html>
